Drugs / LY4257496
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07114601 | Aug 2025 → Apr 2030 expected | breast neoplasm, colorectal neoplasm, endometrium neoplasm, gastric neoplasm +3 | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4257496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07114601 ↗ |
| Modality | Other / unclassified | “LY4257496, a GRPR-Targeted Radioligand Therapy” NCT07114601 ↗ |
| Route | Intravenous | “LY4257496 administered intravenously (IV)” NCT07114601 ↗ |